Rotavirus oral vaccine, live

Name: Rotavirus oral vaccine, live

Dosing & Uses

Not indicated

Dosage Forms & Strengths

oral vaccine

Rotarix

  • Monovalent
  • 89-12 strain (G1P[8] type); ≥10^6 cell culture infective dose

RotaTeq

  • Pentavalent
  • G1 ≥2.2 × 10^6 infectious units
  • G2 ≥2.8 × 10^6 infectious units
  • G3 ≥2.2 × 10^6 infectious units
  • G4 ≥2 × 10^6 infectious units
  • P1A [8] ≥2.3 × 10^6 infectious units of rotavirus attachment protein

Rotavirus Gastroenteritis Prophylaxis

Live, attenuated oral vaccine indicated for immunization to prevent rotavirus gastroenteritis in infants and children

RotaTeq: 3 Dose Regimen

  • Pentavalent vaccine; prevention of rotavirus gastroenteritis caused by the G1, G2, G3, and G4 serotypes, plus attachment protein serotype P7
  • Total of three 2 mL doses administered orally
  • First dose given at 6-12 weeks of age
  • Subsequent doses administered at 4-10 week intervals
  • Third dose should not be given after 32 weeks of age

Rotarix: 2-Dose Regimen

  • Prevention of rotavirus gastroenteritis caused by G1 and non-G1 serotypes (G3, G4, and G9)
  • Total of two 1 mL doses administered orally
  • Administer first dose to infants beginning at 6 weeks of age
  • Administer second dose after an interval of at least 4 weeks and prior to 24 weeks of age

Supporting Data

CDC researchers observed rotavirus-associated diarrhea decreased by 75% and hospitalizations for diarrhea by 33% during 2007-2008 following 2006 introduction of pentavalent rotavirus vaccine; diarrhea-related incidence also decreased among age-matched unvaccinated children (NEJM 2011 Sept22;365:1108-1117)

Up-to-date vaccination schedules available at www.cdc.gov/nip/publications

Share
(web3)